222 related articles for article (PubMed ID: 33350922)
1. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
Baussano I; Sayinzoga F; Tshomo U; Tenet V; Vorsters A; Heideman DAM; Gheit T; Tommasino M; Umulisa MC; Franceschi S; Clifford GM
Emerg Infect Dis; 2021 Jan; 27(1):1-9. PubMed ID: 33350922
[TBL] [Abstract][Full Text] [Related]
2. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda.
Franceschi S; Chantal Umulisa M; Tshomo U; Gheit T; Baussano I; Tenet V; Tshokey T; Gatera M; Ngabo F; Van Damme P; Snijders PJ; Tommasino M; Vorsters A; Clifford GM
Int J Cancer; 2016 Aug; 139(3):518-26. PubMed ID: 26991686
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
Sayinzoga F; Tenet V; Heideman DAM; Sibomana H; Umulisa MC; Franceschi S; Hakizimana JD; Clifford GM; Baussano I
Lancet Glob Health; 2023 Jul; 11(7):e1096-e1104. PubMed ID: 37207683
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
[TBL] [Abstract][Full Text] [Related]
5. Introduction of a National HPV vaccination program into Bhutan.
Dorji T; Tshomo U; Phuntsho S; Tamang TD; Tshokey T; Baussano I; Franceschi S; Clifford G
Vaccine; 2015 Jul; 33(31):3726-30. PubMed ID: 26057136
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme.
Tshomo U; Franceschi S; Dorji D; Baussano I; Tenet V; Snijders PJ; Meijer CJ; Bleeker MC; Gheit T; Tommasino M; Clifford GM
BMC Infect Dis; 2014 Jul; 14():408. PubMed ID: 25047665
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme.
Ngabo F; Franceschi S; Baussano I; Umulisa MC; Snijders PJ; Uyterlinde AM; Lazzarato F; Tenet V; Gatera M; Binagwaho A; Clifford GM
BMC Infect Dis; 2016 May; 16():225. PubMed ID: 27221238
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
9. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
10. Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before-after design.
Machalek D; Rees H; Chikandiwa A; Munthali R; Travill D; Mbulawa Z; Petoumenos K; Delany-Moretlwe S; Kaldor J;
BMJ Open; 2022 Feb; 12(2):e059968. PubMed ID: 35144959
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.
Sayinzoga F; Umulisa MC; Sibomana H; Tenet V; Baussano I; Clifford GM
Vaccine; 2020 May; 38(24):4001-4005. PubMed ID: 32336599
[TBL] [Abstract][Full Text] [Related]
12. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
[TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
15. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
16. Cervical Cancer and Human Papillomavirus Vaccine Awareness Among Married Bhutanese Refugee and Nepali Women in Eastern Nepal.
Bhatta MP; Johnson DC; Lama M; Maharjan B; Lhaki P; Shrestha S
J Community Health; 2020 Jun; 45(3):516-525. PubMed ID: 31696420
[TBL] [Abstract][Full Text] [Related]
17. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
18. HPV vaccine introduction in Rwanda: Impacts on the broader health system.
Torres-Rueda S; Rulisa S; Burchett HE; Mivumbi NV; Mounier-Jack S
Sex Reprod Healthc; 2016 Mar; 7():46-51. PubMed ID: 26826045
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
20. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.
Spayne J; Hesketh T
BMJ Open; 2021 Sep; 11(9):e052016. PubMed ID: 34475188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
